Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023)
Monte Rosa Therapeutics (GLUE) posted quarterly Non Operating Investment Income of -$131000.0 for Q1 2023.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023) Analysis & Trends
Monte Rosa Therapeutics' Non Operating Investment Income history runs 1 years deep, the most recent figure standing at -$131000.0 for Q1 2023.
- In Q1 2023, Non Operating Investment Income changed N/A year-over-year to -$131000.0; the TTM figure through Dec 2023 stood at -$131000.0 (changed N/A YoY), while the FY2023 annual figure was -$131000.0, changed N/A from the prior year.
- Non Operating Investment Income for Q1 2023 stood at -$131000.0.
- The five-year high for Non Operating Investment Income was -$131000.0 in Q1 2023, with the low at -$131000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Monte Rosa Therapeutics | 1.42 Bn | 785.78 Mn | - | - |